Role of ABL Gene Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib and Results of Treatment Shift to Second-Generation Tyrosine Kinase Inhibitors
Sílvia Marcé(Josep Carreras Leukaemia Research Institute), Fuensanta Millá, Imma Portal(Maresme Health Consortium), Lluís Rodríguez(Hospital de l'Esperança), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Javier Grau, Esther Plensa(Hospital de Mataró), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Alberto Fernández de Sevilla(Duran i Reynals Hospital), Diana Domínguez(Institute for Research in Biomedicine), Jorge Medina(Duran i Reynals Hospital), Josep‐María Ribera(Universitat Autònoma de Barcelona), Lurdes Zamora(Universitat Autònoma de Barcelona), Marta Cabezón(Universitat Autònoma de Barcelona), Jordi Ribera(Josep Carreras Leukaemia Research Institute), C. Mauleón Fernández(Hospital Universitari de Girona Doctor Josep Trueta), Patricia Vélez(Hospital Del Mar), Marisol Xandri(Fundación Josep Carreras Contra la Leucemia), Concha Boqué(Institut Català d'Oncologia), Evarist Feliú(Universitat Autònoma de Barcelona)
Cited by 0
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|457
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309